nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.0377	0.0547	CcSEcCtD
Tapentadol—HTR3A—cranial nerve—amyotrophic lateral sclerosis	0.0332	0.164	CbGeAlD
Tapentadol—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.0218	0.0317	CcSEcCtD
Tapentadol—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.0205	0.0298	CcSEcCtD
Tapentadol—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.0205	0.0298	CcSEcCtD
Tapentadol—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0188	0.0273	CcSEcCtD
Tapentadol—HTR3A—nerve—amyotrophic lateral sclerosis	0.017	0.0842	CbGeAlD
Tapentadol—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.0169	0.0245	CcSEcCtD
Tapentadol—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.0163	0.0237	CcSEcCtD
Tapentadol—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.0157	0.0229	CcSEcCtD
Tapentadol—OPRM1—nerve—amyotrophic lateral sclerosis	0.0156	0.0772	CbGeAlD
Tapentadol—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.0153	0.0222	CcSEcCtD
Tapentadol—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0149	0.0217	CcSEcCtD
Tapentadol—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0195	CcSEcCtD
Tapentadol—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0193	CcSEcCtD
Tapentadol—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0114	0.0565	CbGeAlD
Tapentadol—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0163	CcSEcCtD
Tapentadol—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0153	CcSEcCtD
Tapentadol—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0147	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0147	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0099	0.0144	CcSEcCtD
Tapentadol—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00973	0.0481	CbGeAlD
Tapentadol—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0093	0.0135	CcSEcCtD
Tapentadol—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00896	0.013	CcSEcCtD
Tapentadol—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00893	0.013	CcSEcCtD
Tapentadol—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00878	0.0127	CcSEcCtD
Tapentadol—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00865	0.0126	CcSEcCtD
Tapentadol—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00865	0.0126	CcSEcCtD
Tapentadol—Depression—Riluzole—amyotrophic lateral sclerosis	0.00862	0.0125	CcSEcCtD
Tapentadol—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00841	0.0122	CcSEcCtD
Tapentadol—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.0079	0.0115	CcSEcCtD
Tapentadol—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00773	0.0112	CcSEcCtD
Tapentadol—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00773	0.0112	CcSEcCtD
Tapentadol—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00767	0.0111	CcSEcCtD
Tapentadol—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00763	0.0111	CcSEcCtD
Tapentadol—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00761	0.011	CcSEcCtD
Tapentadol—HTR3A—brainstem—amyotrophic lateral sclerosis	0.00731	0.0361	CbGeAlD
Tapentadol—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00726	0.0105	CcSEcCtD
Tapentadol—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00721	0.0105	CcSEcCtD
Tapentadol—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00704	0.0102	CcSEcCtD
Tapentadol—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00701	0.0102	CcSEcCtD
Tapentadol—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.007	0.0102	CcSEcCtD
Tapentadol—Chills—Riluzole—amyotrophic lateral sclerosis	0.00697	0.0101	CcSEcCtD
Tapentadol—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00987	CcSEcCtD
Tapentadol—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00676	0.00981	CcSEcCtD
Tapentadol—OPRM1—brainstem—amyotrophic lateral sclerosis	0.00671	0.0331	CbGeAlD
Tapentadol—Tension—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00963	CcSEcCtD
Tapentadol—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00656	0.00953	CcSEcCtD
Tapentadol—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00633	0.00919	CcSEcCtD
Tapentadol—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00621	0.00902	CcSEcCtD
Tapentadol—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00618	0.00896	CcSEcCtD
Tapentadol—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00607	0.00881	CcSEcCtD
Tapentadol—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00606	0.0088	CcSEcCtD
Tapentadol—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00597	0.00867	CcSEcCtD
Tapentadol—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00862	CcSEcCtD
Tapentadol—Cough—Riluzole—amyotrophic lateral sclerosis	0.0059	0.00856	CcSEcCtD
Tapentadol—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00586	0.0085	CcSEcCtD
Tapentadol—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00575	0.00835	CcSEcCtD
Tapentadol—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00573	0.00832	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00571	0.0083	CcSEcCtD
Tapentadol—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00563	0.00817	CcSEcCtD
Tapentadol—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00558	0.0276	CbGeAlD
Tapentadol—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00556	0.00807	CcSEcCtD
Tapentadol—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00552	0.00801	CcSEcCtD
Tapentadol—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00552	0.00801	CcSEcCtD
Tapentadol—Infection—Riluzole—amyotrophic lateral sclerosis	0.00548	0.00795	CcSEcCtD
Tapentadol—Shock—Riluzole—amyotrophic lateral sclerosis	0.00543	0.00788	CcSEcCtD
Tapentadol—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00541	0.00785	CcSEcCtD
Tapentadol—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00538	0.00781	CcSEcCtD
Tapentadol—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00536	0.00778	CcSEcCtD
Tapentadol—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00533	0.00774	CcSEcCtD
Tapentadol—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00515	0.00748	CcSEcCtD
Tapentadol—OPRD1—nervous system—amyotrophic lateral sclerosis	0.00515	0.0255	CbGeAlD
Tapentadol—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00503	0.0073	CcSEcCtD
Tapentadol—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00499	0.00724	CcSEcCtD
Tapentadol—OPRD1—central nervous system—amyotrophic lateral sclerosis	0.00496	0.0245	CbGeAlD
Tapentadol—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00495	0.00719	CcSEcCtD
Tapentadol—OPRK1—nervous system—amyotrophic lateral sclerosis	0.00494	0.0244	CbGeAlD
Tapentadol—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00492	0.00714	CcSEcCtD
Tapentadol—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00491	0.0243	CbGeAlD
Tapentadol—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0049	0.00712	CcSEcCtD
Tapentadol—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00486	0.00705	CcSEcCtD
Tapentadol—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0048	0.00696	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00476	0.00691	CcSEcCtD
Tapentadol—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00476	0.0069	CcSEcCtD
Tapentadol—OPRK1—central nervous system—amyotrophic lateral sclerosis	0.00475	0.0235	CbGeAlD
Tapentadol—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00685	CcSEcCtD
Tapentadol—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00469	0.0232	CbGeAlD
Tapentadol—OPRK1—cerebellum—amyotrophic lateral sclerosis	0.00465	0.023	CbGeAlD
Tapentadol—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00455	0.0066	CcSEcCtD
Tapentadol—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00438	0.00636	CcSEcCtD
Tapentadol—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.00417	0.0206	CbGeAlD
Tapentadol—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00406	0.0059	CcSEcCtD
Tapentadol—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00396	0.00574	CcSEcCtD
Tapentadol—OPRD1—brain—amyotrophic lateral sclerosis	0.00394	0.0195	CbGeAlD
Tapentadol—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.0039	0.00567	CcSEcCtD
Tapentadol—HTR3A—nervous system—amyotrophic lateral sclerosis	0.00383	0.0189	CbGeAlD
Tapentadol—OPRK1—brain—amyotrophic lateral sclerosis	0.00377	0.0187	CbGeAlD
Tapentadol—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00548	CcSEcCtD
Tapentadol—HTR3A—central nervous system—amyotrophic lateral sclerosis	0.00369	0.0182	CbGeAlD
Tapentadol—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00529	CcSEcCtD
Tapentadol—OPRM1—nervous system—amyotrophic lateral sclerosis	0.00351	0.0174	CbGeAlD
Tapentadol—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00509	CcSEcCtD
Tapentadol—Rash—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00505	CcSEcCtD
Tapentadol—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00504	CcSEcCtD
Tapentadol—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00347	0.0171	CbGeAlD
Tapentadol—Headache—Riluzole—amyotrophic lateral sclerosis	0.00346	0.00502	CcSEcCtD
Tapentadol—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00342	0.0169	CbGeAlD
Tapentadol—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.00338	0.0167	CbGeAlD
Tapentadol—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00476	CcSEcCtD
Tapentadol—HTR3A—brain—amyotrophic lateral sclerosis	0.00293	0.0145	CbGeAlD
Tapentadol—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00292	0.0144	CbGeAlD
Tapentadol—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00281	0.0139	CbGeAlD
Tapentadol—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00269	0.0133	CbGeAlD
Tapentadol—OPRM1—brain—amyotrophic lateral sclerosis	0.00269	0.0133	CbGeAlD
Tapentadol—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00257	0.0127	CbGeAlD
Tapentadol—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00248	0.0122	CbGeAlD
Tapentadol—SLC6A4—brain—amyotrophic lateral sclerosis	0.00223	0.011	CbGeAlD
Tapentadol—SLC6A2—brain—amyotrophic lateral sclerosis	0.00197	0.00972	CbGeAlD
Tapentadol—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00141	0.00696	CbGeAlD
Tapentadol—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00136	0.0067	CbGeAlD
Tapentadol—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00133	0.00655	CbGeAlD
Tapentadol—OPRK1—Mecp2 and Associated Rett Syndrome—BDNF—amyotrophic lateral sclerosis	0.0011	0.0101	CbGpPWpGaD
Tapentadol—CYP2D6—brain—amyotrophic lateral sclerosis	0.00108	0.00532	CbGeAlD
Tapentadol—UGT2B7—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000974	0.00896	CbGpPWpGaD
Tapentadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000968	0.0089	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000953	0.00876	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000915	0.00841	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000863	0.00794	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000863	0.00794	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000863	0.00794	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000852	0.00784	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000824	0.00758	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000811	0.00746	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000803	0.00738	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000791	0.00728	CbGpPWpGaD
Tapentadol—UGT2B7—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000745	0.00685	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—CD40LG—amyotrophic lateral sclerosis	0.00072	0.00662	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000716	0.00658	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000704	0.00648	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000698	0.00642	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000677	0.00623	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00067	0.00616	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000635	0.00584	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000625	0.00575	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000609	0.0056	CbGpPWpGaD
Tapentadol—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000605	0.00557	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000595	0.00547	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000595	0.00547	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000594	0.00546	CbGpPWpGaD
Tapentadol—OPRM1—Opioid Signalling—PLA2G4A—amyotrophic lateral sclerosis	0.000581	0.00535	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00058	0.00533	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000557	0.00513	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000549	0.00505	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000539	0.00495	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000538	0.00495	CbGpPWpGaD
Tapentadol—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000523	0.00481	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000518	0.00477	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000516	0.00475	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000502	0.00462	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000497	0.00457	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000493	0.00454	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000489	0.0045	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000487	0.00448	CbGpPWpGaD
Tapentadol—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000481	0.00442	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000472	0.00434	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000467	0.0043	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000467	0.0043	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000457	0.00421	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000447	0.00411	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00044	0.00404	CbGpPWpGaD
Tapentadol—UGT2B7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000436	0.00401	CbGpPWpGaD
Tapentadol—UGT2B7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00043	0.00395	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000421	0.00387	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000416	0.00383	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000411	0.00378	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00041	0.00377	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000404	0.00371	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000399	0.00367	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000375	0.00345	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000372	0.00342	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00036	0.00331	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000357	0.00329	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000354	0.00326	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000351	0.00322	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000349	0.00321	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000342	0.00315	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000339	0.00312	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000334	0.00307	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000334	0.00307	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000334	0.00307	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000307	0.00283	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000305	0.00281	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000304	0.0028	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000303	0.00279	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000296	0.00272	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000295	0.00271	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000286	0.00263	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000284	0.00261	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000271	0.0025	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000271	0.0025	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000267	0.00246	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000262	0.00241	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000261	0.0024	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.00026	0.00239	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000259	0.00238	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000253	0.00233	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000251	0.00231	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000251	0.00231	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000248	0.00228	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000244	0.00224	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000241	0.00222	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000239	0.0022	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000235	0.00216	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000232	0.00213	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000232	0.00213	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000231	0.00212	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000229	0.00211	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000223	0.00205	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000223	0.00205	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000222	0.00204	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000219	0.00202	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000217	0.002	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000211	0.00194	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00021	0.00194	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000209	0.00192	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000206	0.0019	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000203	0.00187	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000196	0.0018	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000189	0.00174	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000185	0.0017	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000183	0.00168	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000179	0.00165	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000174	0.0016	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000172	0.00158	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	0.000169	0.00155	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000166	0.00153	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000164	0.00151	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000164	0.00151	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000157	0.00144	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000157	0.00144	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000156	0.00143	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000154	0.00142	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000153	0.00141	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000152	0.0014	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000151	0.00139	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00015	0.00138	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000149	0.00137	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000146	0.00134	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000144	0.00132	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000143	0.00132	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000142	0.0013	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000139	0.00128	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	0.000137	0.00126	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000135	0.00124	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000133	0.00122	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000128	0.00118	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000128	0.00117	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000128	0.00117	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000126	0.00116	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000125	0.00115	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000124	0.00114	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000124	0.00114	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000122	0.00112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000119	0.00109	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000117	0.00108	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000117	0.00108	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000117	0.00107	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000117	0.00107	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000116	0.00107	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000116	0.00107	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000114	0.00105	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000113	0.00104	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.00011	0.00101	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000109	0.001	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000108	0.000997	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000108	0.000997	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000108	0.000997	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000107	0.000987	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000106	0.000978	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000105	0.000965	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000104	0.000956	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000103	0.000946	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000102	0.000938	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000101	0.00093	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.98e-05	0.000917	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.89e-05	0.000909	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	9.38e-05	0.000863	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.32e-05	0.000857	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	9.3e-05	0.000855	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	9.22e-05	0.000848	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.21e-05	0.000847	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9.19e-05	0.000845	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.12e-05	0.000838	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.87e-05	0.000816	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.54e-05	0.000786	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	8.48e-05	0.00078	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	8.41e-05	0.000773	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.06e-05	0.000741	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.01e-05	0.000737	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	7.7e-05	0.000708	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.63e-05	0.000702	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	7.5e-05	0.000689	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.49e-05	0.000689	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.45e-05	0.000685	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.05e-05	0.000648	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.03e-05	0.000646	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	6.99e-05	0.000643	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.85e-05	0.00063	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	6.81e-05	0.000626	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.69e-05	0.000615	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.53e-05	0.000601	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	6.45e-05	0.000593	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	6.43e-05	0.000591	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	6.37e-05	0.000586	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.33e-05	0.000582	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.14e-05	0.000565	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.06e-05	0.000557	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.94e-05	0.000546	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	5.93e-05	0.000546	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	5.88e-05	0.000541	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.87e-05	0.00054	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.73e-05	0.000527	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.66e-05	0.00052	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	5.64e-05	0.000518	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.57e-05	0.000512	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.43e-05	0.000499	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.39e-05	0.000495	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.36e-05	0.000493	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	5.3e-05	0.000487	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.05e-05	0.000465	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	4.87e-05	0.000448	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.84e-05	0.000445	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.83e-05	0.000444	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	4.83e-05	0.000444	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.76e-05	0.000438	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	4.58e-05	0.000421	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.55e-05	0.000419	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.43e-05	0.000407	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.41e-05	0.000405	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.18e-05	0.000384	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.02e-05	0.00037	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.86e-05	0.000355	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.74e-05	0.000344	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.66e-05	0.000337	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.31e-05	0.000305	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.21e-05	0.000296	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.14e-05	0.000289	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.09e-05	0.000285	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.04e-05	0.000279	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.02e-05	0.000278	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.85e-05	0.000262	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.82e-05	0.000259	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.73e-05	0.000251	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.66e-05	0.000245	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.62e-05	0.000241	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.62e-05	0.000241	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.6e-05	0.000239	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	0.000221	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.39e-05	0.00022	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.39e-05	0.000219	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.38e-05	0.000219	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.25e-05	0.000207	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	2.15e-05	0.000198	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.06e-05	0.000189	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.02e-05	0.000186	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.98e-05	0.000182	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.96e-05	0.00018	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.81e-05	0.000166	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.53e-05	0.00014	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.47e-05	0.000136	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.36e-05	0.000125	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.34e-05	0.000124	CbGpPWpGaD
